Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues
Winter Park, Florida--(Newsfile Corp. - October 26, 2026) - Adia Med Inc. (OTCQB: ADIA) today reported interim safety observations from the first cohort of its randomized Phase 1/2 investigational study in children with autism spectrum disorder (ASD). Investigators reported no serious adverse events in either study arm and no events requiring reporting to the Institutional Review Board (IRB). Enrollment continues under the protocol's staggered schedule, and first-cohort participants remain in...
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


